New obesity drug combo tested in major safety trial
Disease control
Completed
This study tested if a new drug called VTX3232 is safe and well-tolerated when taken alone or combined with the established weight-loss medication semaglutide. About 176 adults with obesity received either the new drug, a placebo, or combinations of these for 12 weeks. The main g…
Phase: PHASE2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC